Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Часто задаваемые вопросы
В каком секторе работает Centessa Pharmaceuticals PLC ADR (CNTA)?
Centessa Pharmaceuticals PLC ADR относится к сектору Здравоохранение.
Какова текущая цена акций Centessa Pharmaceuticals PLC ADR (CNTA)?
По последним данным, цена акций Centessa Pharmaceuticals PLC ADR составляет 40,50 $, предыдущее закрытие — 40,50 $.
Выплачивает ли Centessa Pharmaceuticals PLC ADR (CNTA) дивиденды?
Нет, Centessa Pharmaceuticals PLC ADR не выплачивает дивиденды.
Какой бета-коэффициент (волатильность) у Centessa Pharmaceuticals PLC ADR (CNTA)?
У компании Centessa Pharmaceuticals PLC ADR бета 1.121, что означает, что её волатильность примерно соответствует рыночной.
